All In Biotech

Drug Trial Radar · NCT00295594

Comparing Efficacy & Safety of Tacrolimus With/Without MMF or Monoclonal Anti-IL2R Antibody in Liver Transplantation.

An Open, Randomised, Multicenter, Clinical Study to Compare the Safety and Efficacy of Tacrolimus and Minimal Steroids in Combination With Either a Monoclonal Anti-IL2R Antibody (Daclizumab) or Mycophenolate Mofetil in Liver Allograft Transplantation.

Last checked: Nov 20, 2026Latest source record: Aug 26, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 627 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

627

Actual

Start

Mar 2005

Primary completion

Jun 2007

Study completion Jun 2007

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Feb 24, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the efficacy and safety of two regimens containing tacrolimus and minimal steroids together with either monoclonal anti-IL2R antibodies (daclizumab) or mycophenolate mofetil.

Conditions

  • Liver Transplantation

Interventions

  • tacrolimusDrug

    Immunosuppression

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of and time to first biopsy proven acute rejection which requires treatment within 3 months following transplantationTime frame: 3 months

Locations

41 sites in 11 countries. Site status is shown where the registry gives one.

  • Site not named

    Ghent, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Liège, Belgium

  • Site not named

    Copenhagen, Denmark

  • Site not named

    Helsinki, Finland

  • Site not named

    Bonn, Germany

  • Site not named

    Erlangen, Germany

  • Site not named

    Essen, Germany

  • Site not named

    Hamburg, Germany

  • Site not named

    Hanover, Germany

  • Site not named

    Kiel, Germany

  • Site not named

    Mainz, Germany

  • Site not named

    Budapest, Hungary

  • Site not named

    Bari, Italy

  • Site not named

    Bergamo, Italy

  • Site not named

    Milan, Italy

  • Site not named

    Milan, Italy

  • Site not named

    Naples, Italy

  • Site not named

    Padova, Italy

  • Site not named

    Palermo, Italy

  • Site not named

    Udine, Italy

  • Site not named

    Szczecin, Poland

  • Site not named

    Wroclaw, Poland

  • Site not named

    A Coruña, Spain

  • Site not named

    Barcelona, Spain

  • Site not named

    Córdoba, Spain

  • Site not named

    Granada, Spain

  • Site not named

    Madrid, Spain

  • Site not named

    Madrid, Spain

  • Site not named

    Madrid, Spain

  • Site not named

    Murcia, Spain

  • Site not named

    Pamplona, Spain

  • Site not named

    Santiago, Spain

  • Site not named

    Seville, Spain

  • Site not named

    Valencia, Spain

  • Site not named

    Gothenburg, Sweden

  • Site not named

    Uppsala, Sweden

  • Site not named

    Bern, Switzerland

  • Site not named

    Zurich, Switzerland

  • Site not named

    Leeds, United Kingdom

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.